Christopher I. Wright - 31 May 2024 Form 4 Insider Report for Alkermes plc. (ALKS)

Role: Director
Signature: /s/ Shantale Greenson, attorney-in-fact for Christopher I. Wright
Issuer symbol: ALKS
Transactions as of: 31 May 2024
Net transactions value: +$25,411
Form type: 4
Filing time: 04 Jun 2024, 17:05:16 UTC
Previous filing: 10 Jul 2023
Next filing: 10 Jun 2024
SEC: View on sec.gov

Quoteable Key Fact

"Christopher I. Wright filed Form 4 for Alkermes plc. (ALKS) on 04 Jun 2024."

Quick Takeaways

This page summarizes Christopher I. Wright's Form 4 filing for Alkermes plc. (ALKS).
8 reported transactions and 8 derivative rows are listed below.
Filing timestamp: 04 Jun 2024, 17:05.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALKS	Non Qualified Stock Option (Right to Buy)	Other	$398	+14	+2%	$28.40	728	17 Nov 2023	Ordinary Shares	14	$28.40	Direct	F1, F2
transaction	ALKS	Non Qualified Stock Option (Right to Buy)	Other	$10,082	+355	+2%	$28.40	18,128	17 Nov 2023	Ordinary Shares	355	$28.40	Direct	F1, F3
transaction	ALKS	Restricted Stock Unit Award	Other		+129	+2%		6,602	17 Nov 2023	Ordinary Shares	129		Direct	F1, F4, F5
transaction	ALKS	Non Qualified Stock Option (Right to Buy)	Other	$7,129	+231	+2%	$30.86	11,785	17 Nov 2023	Ordinary Shares	231	$30.86	Direct	F1, F2
transaction	ALKS	Non Qualified Stock Option (Right to Buy)	Other	$7,803	+254	+2%	$30.72	12,986	17 Nov 2023	Ordinary Shares	254	$30.72	Direct	F1, F6
transaction	ALKS	Restricted Stock Unit Award	Other		+119	+2%		6,104	17 Nov 2023	Ordinary Shares	119		Direct	F1, F4, F7
transaction	ALKS	Restricted Stock Unit Award	Award	$0	+8,013		$0.000000	8,013	31 May 2024	Ordinary Shares	8,013		Direct	F4, F8
transaction	ALKS	Non Qualified Stock Option (Right to Buy)	Award	$0	+17,492		$0.000000	17,492	31 May 2024	Ordinary Shares	17,492	$23.40	Direct	F9

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.
F2	These options are fully vested in accordance with their terms.
F3	Shares subject to the stock option award vest in three equal annual installments commencing on 6/8/2023.
F4	Each restricted stock unit represents a contingent right to receive one ordinary share.
F5	Shares subject to the restricted stock unit award vest in three equal annual installments commencing on 6/8/2023.
F6	Shares subject to the stock option award vest and become exercisable in full on 6/29/2024.
F7	Shares subject to the restricted stock unit award vest in full on 6/29/2024.
F8	Shares subject to the restricted stock unit award vest in full on 5/31/2025.
F9	Shares subject to the stock option award vest and become exercisable in full on 5/31/2025.

EXHIBIT LIST: Exhibit 24.1 - Power of Attorney